GEN Exclusives

More »

GEN News Highlights

More »
Mar 16, 2012

ThromboGenics Gets €75M Up Front in Eyecare Commercialization Deal with Alcon

  • Alcon is paying ThromboGenics €75 million to take over commercialization of ocriplasmin in all markets outside the U.S. ThromboGenics has completed a clinical development program that included two successful Phase III studies that have shown that ocriplasmin could play an important role in treating symptomatic vitreomacular adhesion (VMA) including macular hole.

    Thrombogenics is also entitled to a €90 million in near-term milestone payments, future milestones of €210 million, and royalties. The company will concentrate on commercializing ocriplasmin in the U.S. where it plans to build its commercial and medical organization to support the product’s anticipated launch within the next 12 months.

    Under the agreement, ThromboGenics will still have a strategic and focused operational role in the commercialization of ocriplasmin in the five largest European markets, enabling it to build the foundation for an expanding ophthalmology franchise. In addition to the commercial introduction of ocriplasmin in markets outside the U.S., the agreement specifies that Alcon and ThromboGenics will work together and share the costs to further develop new clinical applications of the product that the companies will introduce in their respective territories.


Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...

Unable to get Jobs Listings.

More »

GEN Poll

More » Poll Results »

Biosimilars

Compared to the original biologics, do you think biosimilars run the risks of being less effective and causing more side effects?